Im­munomedics lays out its case for an ac­cel­er­at­ed OK of IM­MU-132 in triple-neg­a­tive breast can­cer

A lit­tle over a month af­ter Seat­tle Ge­net­ics $SGEN snapped up the glob­al rights to Im­munomedics lead can­cer drug IM­MU-132 (sac­i­tuzum­ab govite­can) in a $2 bil­lion deal, in­clud­ing $300 mil­lion in cash, the Mor­ris Plains, NJ-based biotech de­tailed the da­ta they plan to hus­tle to the FDA from its pos­i­tive mid-stage study for triple-neg­a­tive breast can­cer.

While the study was a fair­ly small, sin­gle-arm probe of ef­fi­ca­cy and safe­ty, the two part­ners are plan­ning the short­est route pos­si­ble to see if they can get an ac­cel­er­at­ed ap­proval while the ther­a­py nav­i­gates a Phase III piv­otal study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER